Format

Send to

Choose Destination
J Asthma. 2013 Apr;50(3):296-301. doi: 10.3109/02770903.2012.757780. Epub 2013 Jan 28.

Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry.

Author information

1
Department of Pneumology, Hospital Xeral-Calde, Rua Doutor Ochoa, Lugo, Spain.

Erratum in

  • J Asthma. 2013 Jun;50(5):537-9.

Abstract

AIM:

To evaluate the effectiveness of omalizumab in non-atopic asthma.

METHODS:

Using data from a multicenter registry of severe asthma, we evaluated and compared the clinical outcome of 29 omalizumab-treated severe non-atopic asthmatics with 266 omalizumab-treated severe allergic asthmatics. Effectiveness was assessed by considering severe exacerbations, pulmonary function, the Global Evaluation of Treatment Effectiveness (GETE) scale, and Asthma Control Test (ACT).

RESULTS:

Omalizumab demonstrated significant improvement in the clinical status of non-atopic asthmatics as measured by GETE, which rose from 1.6 ± 1.1 to 2.8 ± 0.9 [corrected] at 4 months (p = .0215) to 2.9 ± 0.9 at 1 year (p = .0093) and to 3.4 ± 0.6 at 2 years (p = .0078), and by the ACT, which increased from 13.3 ± 5.5 [corrected] to 17.5 ± 5.4 at 4 months (p = .0236) to 17.9 ± 4.8 at 1 year (p = .0136) and to 20.6 ± 3.9 at 2 years (p = .0024). Forced expiratory volume in 1 second (FEV1) improved from 61.0 ± 19.4% to 65.1 ± 17.2 at 4 months to 64.1 ± 24.7 at 1 year and to 67.3 ± 23.0% [corrected] at 2 years, but without significant differences between initial and follow-up measurements (p = .52, .91, and .45, respectively) and exacerbations decreased from 3.1 ± 3.5 to 1.9 ± 2.8 at 1 year (p = .1709) to 1.8 ± 4.4 at 2 years (p = .2344). The results were not significantly different from those obtained in atopic asthmatics.

CONCLUSION:

Anti-IgE therapy can be effective in non-atopic severe asthma.

PMID:
23350994
DOI:
10.3109/02770903.2012.757780
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center